Form 4: Tarsus Pharmaceuticals Director Elizabeth Yeu Lin Acquires Stock Options and Restricted Stock Units

Director Elizabeth Yeu Lin acquired stock options and restricted stock units in Tarsus Pharmaceuticals, Inc. related to her service as a non-employee director.

Summary

• Elizabeth Yeu Lin, a director at Tarsus Pharmaceuticals, acquired stock options and restricted stock units (RSUs) on June 13, 2024.
• The stock options grant the right to buy 5,000 shares of common stock at an exercise price of $33.14 per share and will vest on June 12, 2034.
• Additionally, 3,350 RSUs were granted, each representing a contingent right to receive one share of the company's common stock.
• Both the stock options and RSUs were granted in connection with Lin's service as a non-employee director as of the company's 2024 annual meeting of stockholders.
• The options and RSUs vest in full on the one-year anniversary of the grant date, contingent upon continuous service as a non-employee director.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of equity compensation for directors, indicating a positive alignment of interests. No immediate financial impact is apparent, but it signals confidence in the company's future.

Positives

• The grant of stock options and RSUs aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a non-employee director.

Future Outlook

The director's holdings will increase if the stock price appreciates above the exercise price of $33.14, and if the director remains in continuous service.

Industry Context

Granting stock options and RSUs to directors is a common practice to align their interests with those of the shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a standard practice in the pharmaceutical industry.
• Companies like Amgen and Gilead Sciences also use equity-based compensation to attract and retain qualified board members.
• The vesting schedule of one year is also typical, aligning with industry norms for director compensation.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align director interests with long-term company performance.

Key Dates